Rare Disease Weekly Report: Progressive Muscular Dystrophy Included in Outpatient Special Disease Coverage; New Therapies Emerge for DEEs and gMG Patients
UgeneX
Ophthalmic Disease Treatment Drug Developer
-Policy Focus-
Jiangsu Province Includes Progressive Muscular Dystrophy in Special Outpatient Diseases Covered by Medical Insurance
On October 9, the Office of Jiangsu Provincial Medical Security Bureau issued the "Notice on Including Progressive Muscular Dystrophy in the Special Outpatient Disease Coverage of Basic Medical Insurance". This notice will further strengthen the outpatient coverage of basic medical insurance for patients with progressive muscular dystrophy, better meeting the outpatient medical and medication needs of this group.
Source:Office Document of Jiangsu Provincial Medical Security Bureau
-Drug Progress-
Bexicaserin Granted Breakthrough Therapy Designation in China
On October 13, the candidate drug Bexicaserin was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of Developmental and Epileptic Encephalopathy (DEE).pileptic Encephalopathies, DEEs) related seizures. The drug was previously approved by the U.S. FFDA Breakthrough Therapy Designation, this designation will help accelerate its clinical development and approval process in China, providing new treatment hope for this patient population with rare severe epilepsy.
Source:Lundbeck
New Drug for Generalized Myasthenia Gravis (gMG) Approved for Marketing in China
On October 11, Zilucoplan Sodium, an innovative drug for the treatment of generalized myasthenia gravis (gMG) in adults who are positive for anti-acetylcholine receptor (AChR) antibodies, was approved for marketing by the China National Medical Products Administration (NMPA). This approval makes Zilucoplan Sodium the world’s first and only next-generation C5 complement inhibitor that can be administered via subcutaneous injection and self-administered by patients, providing a more convenient treatment option for gMG patients in China.
Source:National Medical Products Administration
Gene Therapy for Friedreich's Ataxia ObtainsFDA Accelerated Approval Intention
On October 7, the FDA expressed an "open attitude" toward the accelerated approval of a gene therapy for Friedreich’s ataxia. This therapy targets a rare neurodegenerative disease and is currently refining manufacturing process information to supplement the application based on regulatory recommendations. The FDA's positive stance may help reduce the sample size and time frame for critical clinical trials.
Source:Lexeo Therapeutics
-Industry Trends-
Conference on Achondroplasia Held in Hangzhou Focuses on Multidisciplinary Treatment Exploration
On October 12, a patient gathering for individuals with achondroplasia was held in Hangzhou. Experts from multiple medical institutions exchanged insights on clinical practices and patient support, discussing more systematic multidisciplinary treatment plans. Achondroplasia is caused by variations in the FGFR3 gene, affecting approximately 1 in every 20,000 children, with the average adult height of patients typically being less than 130 centimeters.
Source:The Second Affiliated Hospital of Zhejiang University School of Medicine
Chinese-Produced AAV Vector Gene Therapy Receives International Licensing Collaboration
On October 9, Suzhou UgeneX Therapeutics Co., Ltd. announced a strategic agreement with British biotech company AviadoBio, granting it an exclusive option for the overseas development and commercialization of its optogenetics pipeline UGX202, aiming to improve vision for patients with retinal degenerative diseases through optogenetics technology.
Source:UgeneX
Nearly 70% of FDA Breakthrough Therapies Approved, Rare Disease Drugs Occupy a Key Area
On October 9, according to the latest analysis by Jefferies, from 2013 to 2022, the number of FDA "Breakthrough Therapies" granted has increased significantly. Therapy) recognized new drugs, about 72% were eventually approved for marketing, and about 13% are still under review. The analysis is based on FDA public data, Friends of Cancer Research and Biomedtracker database compilation. Breakthrough therapies are mostly concentrated in rare disease indications, indicating that this field remains a key focus for innovative drug evaluation.
Source:BioSpace
FDA Recognizes Remote Clinical Study Site Model: Third Inspection Result is "No Action Indicated"
On October 8, the FDA conducted the third quality inspection of a Direct-to-Patient clinical research site and concluded with "No Action Indicated," without issuing any Form 483 notifications for corrective actions. This signifies that the innovative research model has once again gained regulatory approval in terms of data quality and participant safety, also reflecting the FDA's continued recognition of the Decentralized Clinical Trial (DCT) model.
Source:Science 37
The information contained in this article is for sharing scientific research and industry trends only, and should not be regarded as medical advice or investment guidance.
The weekly overview information in the field of rare diseases compiled and released by this platform is sourced from publicly available online channels.If there is any infringement, please contact us in time for verification and handling.
